Status:
COMPLETED
Nicotinic Receptor Augmentation of SSRI Antidepressants
Lead Sponsor:
Yale University
Collaborating Sponsors:
Donaghue Medical Research Foundation
Conditions:
Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and ci...
Detailed Description
Mecamylamine for the Treatment of Depression in SSRI-Treated Partial Responders A. Purpose 1. To compare the nicotinic receptor antagonist mecamylamine (MEC) to placebo for the treatment of depressi...
Eligibility Criteria
Inclusion
- Major depression, recurrent outpatients, ages 18-65, smoker or non-smoker, on SSRI monotherapy, depression scores on HDRS-17 item scale or = 12.
Exclusion
- suicidal or homicidal ideation, need for inpatient or partial hospital care, systolic blood pressure \<100 mm Hg, history of hypersensitivity to mecamylamine or its excipients.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00319319
Start Date
January 1 2003
End Date
January 1 2007
Last Update
April 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519